John Nosenzo - Apr 1, 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Apr 1, 2022
Transactions value $
-$1,251
Form type
4
Date filed
4/21/2023, 05:45 PM
Previous filing
Feb 15, 2022
Next filing
Jun 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Sale -$563 -40 -0.05% $14.07 87.3K Apr 1, 2022 Direct F1, F2
transaction BVS Class A Common Stock Sale -$639 -95 -0.11% $6.73 87.2K Jul 1, 2022 Direct F1
transaction BVS Class A Common Stock Sale -$49 -7 -0.01% $7.00* 87.1K Oct 3, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan.
F2 Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan.